Immunotherapy-related DNA damage biomarkers — the assessment of tumor cell DNA damage from immune effector mechanisms (perforin/granzyme, TNF-α, FasL) and normal tissue DNA damage from checkpoint inhibitor toxicity creating the dual clinical trial application — creates the most commercially dynamic market segment, with the DNA Damage Detection Kit Market reflecting...